SecBot SecBot

MIRM drug pipeline

$91.58
−2.6% 1-day · Nov 16
Next catalyst
H1 2027
brelovitug BLA filing
Typical move on FDA news
±3.4%
1-day, median of 14 events
IV rank
No data
No current options data
Rated drugs
3
2 bullish · 1 neutral
Phase 3 trials
1
1 with results posted

Upcoming catalysts

3 dated
  1. Jan 2027
    Volixibat
    Phase 2 primary completion
  2. H1 2027
    brelovitug
    BLA filing · chronic hepatitis delta virus (HDV)
  3. H1 2027
    volixibat
    NDA filing · primary sclerosing cholangitis (PSC)

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 3 (completed)
Time to marketMirum plans to submit a Biologics License Application (BLA) to the FDA in the first half of 2027, supported by the positive AZURE-1 and AZURE-4 results. If accepted and approved, commercial launch could follow in late 2027 or early 2027.

brelovitug Updated Nov 10

H1 2027
Next catalyst
BLA filing · H1 2027 · chronic hepatitis delta virus (HDV)
What to watch

Brelovitug has cleared its two pivotal Phase 3 trials (AZURE-1 and AZURE-4), setting up a BLA submission in H1 2027. The stock already reflects significant optimism (analyst mean target $155 vs ~$94 close), and the next major binary event is the BLA acceptance and subsequent FDA review. Watch for the AZURE-2 head-to-head data against Gilead's Hepcludex, which will determine brelovitug's commercial positioning in a market with one existing approved therapy.

Bull case
  • Brelovitug has now succeeded in two pivotal Phase 3 trials (AZURE-1 and AZURE-4), de-risking its regulatory path significantly. The drug has FDA Breakthrough Therapy and Orphan Drug designations, which could accelerate review. Long-term data showing 100% response in cirrhosis patients is a strong differentiator. Mirum already has a commercial infrastructure and ~$715-720M in annual product sales from approved drugs (Livmarli, bile acid medicines), meaning it can fund the launch without dilutive financing. Analyst consensus is Strong Buy with a mean price target of $155, implying ~66% upside from the November 10 close of $94.42.
Bear case
  • Gilead's Hepcludex (bulevirtide) was approved by the FDA in May 2026 as the first and only approved treatment for chronic HDV, giving it first-mover advantage and established physician familiarity. The AZURE-2 trial is a head-to-head comparison against Hepcludex, and brelovitug's commercial differentiation versus Hepcludex is unproven. HDV is a very small market (estimated ~100,000 patients in the US), limiting peak sales potential. BLA submission is still months away (H1 2027), and the stock already reflects significant gains (up ~13% on orphan drug news alone). Insider sales by CEO Christopher Peetz sold $1.8M of stock on November 4, 2026 at $90/share.
● neutral
Impact
PhaseApproved
Time to marketApproved and launching October 2026 (US); EU marketing authorization application under EMA review. Label expansion for ages 6-12 targeted via sNDA in H1 2027.

ATEBRIOZ zilurgisertib Updated Oct 26

What to watch

The next catalyst is the sNDA submission planned for H1 2027 to expand ATEBRIOZ's label to children aged 6 to <12 years, building on the positive Cohort 2 data announced today. The commercial launch in October 2026 and first quarterly sales disclosure (likely on the Q3 2026 earnings call, Nov 17, 2026) will be the earliest tangible read on adoption. Watch for FDA acceptance of the sNDA and any Priority Review designation, as well as enrollment progress in Cohort 3 (ages 2 to <12).

Bull case
  • First-in-class oral ALK2 inhibitor for FOP addresses a high-unmet-need ultra-rare disease. PROGRESS Cohort 1 data showed near-100% reduction in new heterotopic ossification lesions, supporting FDA approval with Priority Review one day ahead of PDUFA.
  • Positive PROGRESS Cohort 2 topline data (announced Oct 26, 2026) showed zilurgisertib reduced mean HO lesion volume by -8.09 cm³ vs +9.14 cm³ for placebo (treatment difference -14.0 cm³, p=0.003) and no treated patients developed new lesions. This supports an sNDA for ages 6-12 in H1 2027, expanding the addressable pediatric population.
  • Strong institutional accumulation: 18 tracked managers added or doubled MIRM positions in Q2 2026, including FMR LLC (+86.7% to $430M), Price T Rowe (+54.6% to $311M), and Capital World Investors (+59.2% to $135M).
Bear case
  • Ultra-small patient population: FOP affects roughly 800-1,000 patients in the US, capping peak revenue even at ~$750K/year pricing (Citizens analyst estimate per Reuters). Mirum's own estimate of >$200M annual revenue potential is modest for a ~$5.4B market cap company.
  • Already faces two approved FOP competitors: Ipsen's Sohonos (palovarotene, approved Aug 2023) and Regeneron's Pasatru (garetosmab, approved Aug 2026). Sohonos has had weak commercial uptake (~$24M H1 2026 sales) due to safety concerns, suggesting that FOP market penetration is difficult.
  • Insider selling: CFO Eric Bjerkholt sold ~$978K in stock on Sept 14, 2026 at ~$98/share, and CEO Christopher Peetz sold shares totaling ~$2.9M via 10b5-1 plans from Aug-Sept 2026 near $98-100, above the current ~$83 price.
▲ bullish
Impact
PhaseApproved
Time to marketAlready approved and commercialized (first FDA approval September 2021 for Alagille syndrome; PFIC label expansion July 2024; tablet formulation April 2025). A third label expansion for ultra-rare cholestatic liver diseases is expected to be filed with regulators in H1 2027.

LIVMARLI maralixibat Updated Nov 13

What to watch

The next catalyst for LIVMARLI is a regulatory submission for label expansion into ultra-rare cholestatic liver diseases (including biliary atresia) following the positive Phase 3 EXPAND readout. Mirum guided for five potential regulatory submissions across its portfolio in H1 2027; a filing acceptance would be a positive signal. Watch for FDA submission announcements in early 2027.

Bull case
  • LIVMARLI is already a proven commercial product with strong sales momentum: Mirum reported Q3 2026 net product sales of $185.7M and raised full-year 2026 guidance to $715-720M, driven largely by LIVMARLI demand.
  • The Phase 3 EXPAND study succeeded with highly statistically significant results (p=0.0004 for pruritus reduction, p<0.0001 for serum bile acid reduction), positioning LIVMARLI for a third rare liver indication covering biliary atresia and other ultra-rare cholestatic diseases.
  • Analyst consensus is overwhelmingly bullish: 20 of 21 analysts rate MIRM as Buy/Strong Buy/Buy (12 Buy, 8 Strong Buy, 1 Hold), with a mean price target of $154 (65% upside from the $93.33 close) and a high target of $194.
Bear case
  • LIVMARLI already faces competition from other IBAT inhibitors and bile acid modulators in rare cholestatic liver diseases, which could pressure market share and pricing.
  • Insider selling has been notable: CEO Christopher Peetz sold $1.8M in stock on Nov 4, 2026 (via 10b5-1 plan), and director Laura Brege sold ~$1.33M on Nov 11, 2026 (not under a 10b5-1 plan).
  • Several large institutional holders trimmed positions in Q3 2026, including Federated Hermes (-63%), Nuveen (-60%), and Principal Financial (-52%), suggesting some profit-taking at elevated valuations.

Other drugs in filings and trials

no drug report yet
  • volixibat Next: NDA filing · H1 2027 1 trial
  • MRM-3379 Last: Fast Track · Sep 26, 2026
  • CTEXLI Last: Approval · Feb 21, 2025

Past FDA events & how the stock moved

14 events
DateDrugEvent1 day5 days
Nov 3, 2026ATEBRIOZApproval+13.1%—
Nov 3, 2026brelovitugOrphan drug designation+13.1%—
Sep 26, 2026ATEBRIOZPDUFA decision−1.9%−7.5%
Sep 26, 2026MRM-3379Fast Track−1.9%−7.5%
Sep 26, 2026ATEBRIOZNDA filed−1.9%−7.5%
Sep 26, 2026ATEBRIOZPriority review−1.9%−7.5%
Aug 6, 2026MRM-3379Fast Track−4.9%−6.6%
Jun 30, 2026MRM-3379Fast Track−2.1%+4.5%
May 6, 2026MRM-3379Fast Track−2.7%+3.2%
Feb 25, 2026MRM-3379Fast Track−14.2%−13.4%
Dec 31, 2025MRM-3379Fast Track−1.0%+3.5%
Apr 10, 2025LIVMARLIApproval−4.6%−5.7%
Feb 21, 2025CTEXLIApproval−4.2%−10.5%
Sep 29, 2021LIVMARLIApproval+6.2%−7.0%

Clinical trials

3 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
VolixibatA Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary CholangitisPhase 2Active not recruiting333Jan 2027
LIVMARLIAn Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)Phase 3Completed · results84Apr 23, 2025
LIVMARLIA Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).Phase 2Completed · results27Dec 17, 2024